Novartis Submits Femara For Early Adjuvant Treatment Of Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Femara would be first breast cancer drug with adjuvant and extended adjuvant approvals, Novartis says. Supplemental NDA is based on a reduction of the risk of recurrence in the BIG 1-98 trial; the 8,000-patient study is continuing to determine if monotherapy or sequential therapy with tamoxifen is more effective.
You may also be interested in...
Femara Gets Indication for Early-Stage Breast Cancer
Novartis touts a New England Journal of Medicine article stating that letrozole is superior to tamoxifen.
Femara Gets Indication for Early-Stage Breast Cancer
Novartis touts a New England Journal of Medicine article stating that letrozole is superior to tamoxifen.
Pfizer Aromasin Cleared For Early Breast Cancer
Pfizer's oncologic Aromasin (exemestane) received approval Oct. 5 for the adjuvant treatment of early breast cancer in patients crossing over from tamoxifen therapy